SPDR S&P ETF ETF.com segment: Equity: U.S. Competing ETFs: IHE, PJP, FTXH Related ETF Channels: Sectors, Healthcare, Equal-Weighted, U.S., Smart-Beta ETFs, Equity, North America, Find more ETFs with our ETF Screener and Database *Unless otherwise stated, data provided by FactSet. A FUND DESCRIPTION tracks an equal-weighted index of US pharmaceutical companies. FACTSET ANALYTICS INSIGHT offers equal-weighted exposure to roughly 30 US pharmaceutical companies, stretching across all market-cap sizes. 's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. It also introduces a heavy tilt to mid- and smallcaps, which makes for a rather volatile fund relative to the industry. sees significant daily trading volume with small spreads, and underlying liquidity is excellent for block trades. It's also a very Efficient fund, with a low fee and tight tracking that lags by less than 's expense ratio. Overall, is a solid way to capture a less concentrated version of the pharma market. SUMMARY DATA Issuer Brand Inception Date Legal Structure Expense Ratio Assets Under Management Average Daily $ Average Spread (%) State Street Global Advisors SPDR 06/19/06 Open-Ended Fund 0.35% $242.49M $2.35M 0.08% MSCI ESG ANALYTICS INSIGHT The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of April 11, 2019 the SPDR S&P ETF MSCI ESG Fund Quality Score is 4.51 out of 10. PORTFOLIO DATA Weighted Average Market Cap Price / Earnings Ratio Price / Book Ratio $53.50B -7.31 2.79 The fund s Peer Rank reflects the ranking of a fund s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ranks in the 31st percentile within its peer group and in the 19th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage. Distribution Yield Next Ex-Dividend Date Number of Holdings 0.70% 06/24/19 INDEX DATA Index Tracked S&P Select Industry Index Weighting Methodology Index Selection Methodology Equal Market Cap Thomson Reuters US 1 Year PERFORMANCE [as of 04/11/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS -0.54% 3.45% 11.90% -1.67% -1.10% 1.46% 14.24% (NAV) -0.58% 3.41% 11.81% -1.72% -1.07% 1.46% 14.22% S&P Select Industry -0.56% 3.48% 11.90% -1.51% -0.93% 1.60% 14.22% Thomson Reuters US -- -- -- -- -- -- -- All returns over 1 year are annualized. All returns are total returns unless otherwise stated. TOP 10 COUNTRIES
TOP 10 SECTORS TOP 10 HOLDINGS PORTFOLIO MANAGEMENT TAX EXPOSURES FUND STRUCTURE Expense Ratio Median Tracking Difference (12 Mo) Max. Upside Deviation (12 Mo) Max. Downside Deviation (12 Mo) 0.35% -0.20% -0.12% -0.31% Max LT/ST Capital Gains Rate Capital Gains Distributions (3 Year) Tax on Distributions Distributes K1 20.00% / 39.60% -- Qualified dividends No Legal Structure OTC Derivative Use Securities Lending Active Securities Lending Split (Fund/Issuer) ETN Counterparty Open-Ended Fund No Yes 100% / 0% N/A ETN Counterparty Risk N/A Fund Closure Risk Low Portfolio Disclosure Daily
Daily Spread Premium/Discount FACTSET ANALYTICS BLOCK LIQUIDITY As of 04/12/19 5 4 3 2 1 This measurement shows how easy it is to trade a $1 million USD block of. is rated a 5 out of 5. TRADABILITY Avg. Daily Share Average Daily $ Median Daily Share Median Daily ($) Average Spread (%) Average Spread ($) Median Premium / Discount (12 Mo) Max. Premium / Discount (12 Mo) Impediment to Creations Market Hours Overlap Creation Unit Size (Shares) Creation Unit/Day (45 Day Average) Creation Unit Cost (%) Underlying / Unit Open Interest on ETF Options Net Asset Value (Yesterday) ETF.com Implied Liquidity 56,633 $2.35M 45,082 $1.88M 0.08% $0.03-0.02% 0.12% / -0.29% None 100.00% 50,000 0.90 0.01% 0.17% 646 $40.93 5
SECTOR/INDUSTRY BREAKDOWN TOP 10 HOLDINGS PERFORMANCE STATISTICS - NEC Biotechnology & Medical Research - NEC Bio Therapeutic Drugs 77.04% 89.47% 11.26% 10.30% 4.69% -- Elanco Animal Health, Inc. Zoetis, Inc. Class A Perrigo Co. Plc Jazz Plc Pfizer Inc. Nektar Therapeutics Mylan N.V. Merck & Co., Inc. Allergan plc 4.93% 4.91% 4.84% 4.73% 4.64% 4.56% 4.55% 4.49% 4.48% Goodness of Fit (R2) Beta Up Beta Down Beta Downside Standard Deviation 0.56 0.96 1.05 1.03 0.92% Thomson Reuters US Bio Medical Devices 3.00% -- Eli Lilly and Company Total Top 10 Weighting 4.% 46.56% MSCI ESG RATINGS MSCI ESG Quality Score 4.51 / 10 Drug Retailers - NEC Medical Equipment, Supplies & Distribution - NEC Specialty & Advanced 1.72% -- 0.97% -- 0.42% 0.03% Peer Group Percentile Rank Global Percentile Rank SRI Screening Criteria Exposure Exposure to Sustainable Impact Solutions Weighted Average Carbon Intensity (t CO2e/$M Sales) 30.88 19.04 -- 10.38% 35.13 COUNTRIES United States 100.00% 100.00% REGIONS BENCHMARK COMPARISON HOLDINGS Number of Holdings Constituents Shared Holdings 47 26 Shared Holdings Weight 31.62% North America 100.00% 100.00% BENCHMARK COMPARISON SUMMARY ECONOMIC DEVELOPMENT Developed Countries 100.00% 100.00% Number of Holdings Weighted Average Market Cap Price / Earnings Ratio Price / Book Ratio Dividend Yield 47 $53.50B $196.55B -7.31 30.38 2.79 4.89 0.75% 2.39% Concentration Medium High
2019 ETF.com The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional. ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com. [ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Data provider: Terms of Use MSCI ESG Research LLC s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.